BIO-key International Stock Forecast, Price & News

+0.10 (+2.50 %)
(As of 06/11/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume47,694 shs
Average Volume379,150 shs
Market Capitalization$32.06 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive BKYI News and Ratings via Email

Sign-up to receive the latest news and ratings for BIO-key International and its competitors with MarketBeat's FREE daily newsletter.

BIO-key International logo

About BIO-key International

BIO-key International, Inc., together with its subsidiaries, develops and markets fingerprint identification biometric technology, enterprise-ready identity access management solutions, and software solutions to commercial, government, and education customers in the United States and internationally. The company offers BIO-key PortalGuard and PortalGuard IDaaS solutions, a customer-controlled and neutral-by-design cloud-based identity platform that allows customers to integrate with any cloud or on-premise SaaS application, as well as windows device authentication through IAM platform. Its solutions enable its customers to secure their workforces and student populations; and make their partner networks more collaborative. In addition, it provides BIO-key VST and WEB-key products; and Civil and Large-Scale ID Infrastructure solutions develops finger-based biometric technology. Further, it offers finger scanners for enterprise and consumer markets under SideSwipe, EcoID, and SidePass brand names. The company was formerly known as SAC Technologies and changed its name to BIO-key International, Inc. in 2002. BIO-key International, Inc. was founded in 1993 and is headquartered in Wall, New Jersey.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.53 out of 5 stars

Computer And Technology Sector

352nd out of 1,587 stocks

Computer & Office Equipment Industry

9th out of 27 stocks

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

BIO-key International (NASDAQ:BKYI) Frequently Asked Questions

Is BIO-key International a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BIO-key International in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" BIO-key International stock.
View analyst ratings for BIO-key International
or view top-rated stocks.

What stocks does MarketBeat like better than BIO-key International?

Wall Street analysts have given BIO-key International a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but BIO-key International wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting BIO-key International?

BIO-key International saw a decline in short interest in the month of May. As of May 28th, there was short interest totaling 486,800 shares, a decline of 14.2% from the May 13th total of 567,600 shares. Based on an average daily trading volume, of 265,400 shares, the days-to-cover ratio is currently 1.8 days. Approximately 6.9% of the company's stock are short sold.
View BIO-key International's Short Interest

When is BIO-key International's next earnings date?

BIO-key International is scheduled to release its next quarterly earnings announcement on Friday, August 13th 2021.
View our earnings forecast for BIO-key International

How were BIO-key International's earnings last quarter?

BIO-key International, Inc. (NASDAQ:BKYI) issued its earnings results on Thursday, May, 13th. The technology company reported ($0.09) EPS for the quarter, topping the Zacks' consensus estimate of ($0.16) by $0.07. The technology company had revenue of $1.89 million for the quarter. BIO-key International had a negative net margin of 167.90% and a negative trailing twelve-month return on equity of 45.22%.
View BIO-key International's earnings history

How has BIO-key International's stock been impacted by COVID-19 (Coronavirus)?

BIO-key International's stock was trading at $1.18 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, BKYI shares have increased by 247.5% and is now trading at $4.10.
View which stocks have been most impacted by COVID-19

What guidance has BIO-key International issued on next quarter's earnings?

BIO-key International updated its FY 2021 earnings guidance on Tuesday, June, 8th. The company provided EPS guidance of $- for the period. The company issued revenue guidance of $8 million-12 million, compared to the consensus revenue estimate of $9 million.

What price target have analysts set for BKYI?

1 brokers have issued 12 month price objectives for BIO-key International's stock. Their forecasts range from $6.00 to $6.00. On average, they expect BIO-key International's stock price to reach $6.00 in the next year. This suggests a possible upside of 46.3% from the stock's current price.
View analysts' price targets for BIO-key International
or view top-rated stocks among Wall Street analysts.

Who are BIO-key International's key executives?

BIO-key International's management team includes the following people:
  • Mr. Michael W. DePasquale, Chairman & CEO (Age 66, Pay $327.22k)
  • Mr. Kwok Fong Wong, Vice-Chairman of Directors & MD of Hong Kong (Age 58)
  • Ms. Mira K. LaCous, Chief Technology Officer (Age 59, Pay $215.49k)
  • Mr. James David Sullivan, Sr. VP of Strategy & Compliance and Chief Legal Officer (Age 54, Pay $322.24k)
  • Ms. Cecilia C. Welch, Chief Financial Officer (Age 61)
  • Mr. Frederick Corsentino, Chief Revenue Officer
  • Mr. Akintunde Carlton Jeje, Managing Director of Africa

Who are some of BIO-key International's key competitors?

What other stocks do shareholders of BIO-key International own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BIO-key International investors own include Biocept (BIOC), T2 Biosystems (TTOO), iBio (IBIO), Onconova Therapeutics (ONTX), Acasti Pharma (ACST), Co-Diagnostics (CODX), Heat Biologics (HTBX), Tonix Pharmaceuticals (TNXP), VBI Vaccines (VBIV) and Inovio Pharmaceuticals (INO).

What is BIO-key International's stock symbol?

BIO-key International trades on the NASDAQ under the ticker symbol "BKYI."

Who are BIO-key International's major shareholders?

BIO-key International's stock is owned by many different retail and institutional investors. Top institutional shareholders include Geode Capital Management LLC (0.82%) and Millennium Management LLC (0.27%). Company insiders that own BIO-key International stock include James David Sullivan and Michael W Depasquale.
View institutional ownership trends for BIO-key International

Which institutional investors are selling BIO-key International stock?

BKYI stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC.
View insider buying and selling activity for BIO-key International
or view top insider-selling stocks.

Which institutional investors are buying BIO-key International stock?

BKYI stock was purchased by a variety of institutional investors in the last quarter, including Geode Capital Management LLC. Company insiders that have bought BIO-key International stock in the last two years include James David Sullivan, and Michael W Depasquale.
View insider buying and selling activity for BIO-key International
or or view top insider-buying stocks.

How do I buy shares of BIO-key International?

Shares of BKYI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BIO-key International's stock price today?

One share of BKYI stock can currently be purchased for approximately $4.10.

How much money does BIO-key International make?

BIO-key International has a market capitalization of $32.06 million and generates $2.84 million in revenue each year.

How many employees does BIO-key International have?

BIO-key International employs 34 workers across the globe.

What is BIO-key International's official website?

The official website for BIO-key International is

Where are BIO-key International's headquarters?

BIO-key International is headquartered at 3349 HIGHWAY 138 BUILDING A SUITE E, WALL NJ, 07719.

How can I contact BIO-key International?

BIO-key International's mailing address is 3349 HIGHWAY 138 BUILDING A SUITE E, WALL NJ, 07719. The technology company can be reached via phone at 732-359-1100 or via email at [email protected]

This page was last updated on 6/14/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.